



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

PRODUCT INFORMATION



VER-50589

Item No. 13132

CAS Registry No.: 747413-08-7

Formal Name: 5-(5-chloro-2,4-dihydroxyphenyl)-
N-ethyl-4-(4-methoxyphenyl)-3-
isoxazolecarboxamide

MF: C₁₉H₁₇ClN₂O₅


FW: 388.8

Purity: ≥98%

Supplied as: A crystalline solid

Storage: -20°C

Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Description

The heat shock proteins (Hsps) act as molecular chaperones. Hsp90 is an abundant protein with roles in protein folding, cell signaling, and cancer. VER-50589 is an isoxazole compound that inhibits Hsp90 with an IC₅₀ value of 21 nM.¹ It produces a mean cellular antiproliferative GI₅₀ value of 78 nM when tested against a human cancer cell line panel.¹ Consistent with inhibition of Hsp90, VER-50589 induces the expression of Hsp27 and Hsp72 while reducing the client proteins c-Raf, B-Raf, survivin, and PRMT5, causing cell cycle arrest and apoptosis.¹ VER-50589 shows favorable pharmacokinetics and impairs tumor growth in animals.¹ Importantly, glioblastoma cells do not acquire resistance to VER-50589 and resistance to other Hsp90 inhibitors does not produce cross-resistance to VER-50589.²

References

1. Sharp, S.Y., Prodromou, C., Boxall, K., *et al.* Inhibition of the heat shock protein 90 molecular chaperone *in vitro* and *in vivo* by novel, synthetic, potent resorcinylic pyrazole/isoxazole amide analogues. *Mol. Cancer Ther.* **6**(4), 1198-1211 (2007).
2. Gaspar, N., Sharp, S.Y., Pacey, S., *et al.* Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. *Cancer Res.* **69**(5), 1966-1975 (2009).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/13/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM